Key facts
- Orchestra Bio's AI agents track drug development programs and analyze setbacks.
- The acquired team and platform will be integrated into OpenAI's Rosalind suite.
- Financial terms of the acquisition were not disclosed.
OpenAI has acquired Orchestra Bio, a startup specializing in AI agents for drug development, integrating its team and platform into OpenAI's Rosalind life sciences suite. The move aims to streamline the complex and costly process of bringing new medicines to market, which can take up to 15 years and cost over $2.6 billion. Orchestra's AI agents are designed to monitor drug development programs, identify how setbacks impact timelines, and compare potential responses, with scientists retaining final decision-making authority. The acquisition follows a trend of AI companies expanding into the life sciences sector, with rivals like Anthropic also making similar strategic purchases. OpenAI has previously launched AI models for biology and drug discovery, and its CFO has indicated a strategy to share in the value created by its tools in this field.